Schedule 13G ownership disclosure

Avalo Therapeutics, Inc.

Common Stock, par value $0.001 per share · CUSIP: 05338F306

Event date: 2024-12-23

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Affinity Healthcare Fund, LP

    Shares: 550,765.00 · Class: 5.3%

  • Affinity Asset Advisors, LLC

    Shares: 550,765.00 · Class: 5.3%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001999371-24-015946
Form type
SCHEDULE 13G
Filer
Affinity Asset Advisors, LLC
CIK
CIK 1773195
Filed
Dec 31, 2024
Reporting period
Dec 23, 2024
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub